ATLANTA — Federal health officials confirmed Monday that a clinical trial testing a vaccine candidate against a highly pathogenic avian influenza strain has begun enrolling volunteers, marking the first human safety study of an immunization specifically designed to guard against a virus subtype that epidemiologists consider among the most consequential pandemic threats currently circulating in bird and mammal populations worldwide.
The trial, sponsored by the National Vaccine Research Center in partnership with a coalition of academic medical centers across the United States, will initially enroll 210 healthy adult participants between the ages of 18 and 64. Volunteers will receive either one of two dose levels of the experimental vaccine or a placebo, with assignment determined by randomization, and will be monitored over 12 months for immune response, safety signals, and adverse side effects. A second cohort of adults over 65, who tend to mount weaker immune responses to influenza vaccines and who bear a disproportionate burden of severe influenza disease, is expected to begin enrollment later in the year.
The vaccine target is a strain of influenza A identified in surveillance data collected from domestic poultry flocks, wild migratory bird populations, and a small but growing number of mammalian species including dairy cattle and marine mammals over the past three years. Public health authorities have stressed that the current human risk from this strain remains low, with documented human infections numbering in the dozens globally and occurring almost exclusively in individuals with direct, prolonged, and unprotected exposure to infected animals. No sustained human-to-human transmission chain has been confirmed by any national health authority or by the World Health Organization.
However, virologists monitoring the strain have noted with concern that it has acquired several genetic mutations associated in other influenza lineages with enhanced transmissibility and with an increased ability to bind receptors in the human upper respiratory tract, which would favor airborne spread between people. It is this potential future trajectory, rather than the current infection count, that prompted health agencies to accelerate preparedness measures and fund the vaccine trial announced Monday.
We are not responding to an ongoing outbreak in humans, said Dr. Constance Webb, director of pandemic preparedness at the sponsoring research center, at a press briefing held at the agency’s headquarters. We are running this trial because the science tells us this virus has characteristics we need to take seriously, and because the time to build a vaccine library is before you need it, not after. The lesson of recent pandemic history is that speed in the early response phase saves enormous numbers of lives.
The experimental vaccine uses a messenger RNA platform similar in design to the immunizations deployed at scale during the coronavirus pandemic, encoding instructions for the immune system to recognize and mount a response against the hemagglutinin protein on the surface of the target strain. Researchers noted that the mRNA approach allows the candidate vaccine to be updated relatively rapidly if the virus mutates in ways that alter the hemagglutinin structure, a significant operational advantage over older egg-based influenza vaccine production methods that can require four to six months to scale to pandemic volumes.
Preclinical data submitted to regulatory authorities showed the vaccine candidate generated strong and durable antibody and T-cell responses in ferret models, which are the standard preclinical animal system for influenza research, and produced no serious adverse events across multiple rodent and primate studies. Regulatory agencies in the United States and the European Union have granted expedited review status to the trial protocol, allowing it to proceed on an accelerated timeline compared with standard clinical development schedules without waiving any safety evaluation requirements.
Global health observers have characterized the trial as evidence that pandemic preparedness infrastructure rebuilt after the coronavirus pandemic is beginning to translate into concrete and proactive scientific action. The World Health Organization’s global influenza surveillance network has flagged the target strain as a priority pathogen requiring active vaccine and antiviral therapeutic development since early 2023, and several other countries including the United Kingdom, Japan, and Australia have initiated parallel preparedness programs.
The timeline for potential emergency use authorization, should the trial produce favorable data, remains uncertain. Researchers cautioned that the primary objective of the current phase is to establish a safety profile and characterize the nature of the immune response, not to demonstrate population-level clinical efficacy — a threshold that would require larger and longer trials and, under most regulatory frameworks, evidence of actual human disease burden at a scale that health authorities are actively working to prevent from materializing. A readout of preliminary safety and immunogenicity results is expected by the first quarter of next year, at which point decisions about advancing to a larger efficacy trial would be made in consultation with regulatory bodies and international public health partners.